Tilray acquires UK medical platform Lyphe; files $180M ATM for beverage expansion

Tilray Brands, Inc.

Acquired Lyphe Group, a UK medical cannabis clinic/pharmacy; dispensed ~150K units, treated 16K+ patients; expected accretive in 2027.
Filed ATM equity program of up to $180M to invest in global beverage platform; managed by Jefferies, TD Securities, Roth Capital.
BrewDog (acquired six weeks ago) stabilizing; expects cash-flow positive in 2027; investing in brand and brewpub modernization.
Plans to launch Hi*Ball Energy in UK in May; evaluating US medical cannabis rescheduling and CMS pilot program.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tilray Brands, Inc. entered into Sales Agreement with Jefferies LLC, TD Securities (USA) LLC and Roth Capital Partners, LLC valued at up to $180,000,000 (effective 2026-04-15).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC, TD Securities (USA) LLC and Roth Capital Partners, LLC
Value: up to $180,000,000
Effective: 2026-04-15

Exact text from the filing

On April 15, 2026 Tilray Brands, Inc. (the “ Company ” or “ Tilray ”) entered into an Open Market Sale Agreement SM (the “ Sales Agreement ”) with Jefferies LLC, TD Securities (USA) LLC and Roth Capital Partners, LLC (each, an “ Agent ” and together, the “ Agents ”), pursuant to which the Company may offer and sell shares of the Company’s common stock, par value US$0.0001 per share (the “ Common Stock ”), having an aggregate offering price of up to $180,000,000 from time to time through the Agents, acting as sales agents, or directly to the Agents, acting as principals.

View on SEC.gov

Browse all material agreements →

Tilray Brands, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-014692

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.